Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins
We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.
258 Views
Pharmaceutical Sector: Sequentially Flattish Quarter Expected
4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...
341 Views
Axis Research Scorecard Report - Mar 2022
Axis Top Picks basket has delivered an astounding return of 127% since its inception, notably beating the 89% return reported by the benchmark...
200 Views
Cipla: Rigor on Portfolio Execution and Cash Generation Initiatives to Support Growth
We initiate coverage on CIPLA Ltd (CIPLA) with a BUY rating and a target price of Rs 1,200 (PE 24x for FY24E EPS), implying an upside of 15.5% from...
213 Views
Superior execution drives India/US performance
CIPLA delivered a better-than-expected 3QFY22 performance, led by robust growth in the Domestic Formulation (DF) segment, steadily improving sales...
270 Views